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Summary
Severe oral mucositis is a
critical problem in patients

Purpose: To assess the safety of the superoxide dismutase mimetic GC4419 in combination with radiation and concurrent cisplatin for patients with oral cavity or oropharyngeal
cancer (OCC) and to assess the potential of GC4419 to reduce severe oral mucositis (OM).
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receiving chemoradiation for
oral cavity and oropharynx
cancer. This phase 1/2 dose
and duration escalation study
tested the safety of a daily
60-minute pre-RT infusion
of GC4419, a superoxide
dismutase mimetic. A
maximum tolerated dose was
not reached, safety was
acceptable (nausea/vomiting
and facial paresthesia during
infusion appeared GC4419
doseerelated), and doses of
30 and 90 mg/d for the
duration of radiation were
selected for further study.

Patients and Methods: Patients with locally advanced OCC treated with definitive or
postoperative intensity modulated radiation therapy (IMRT) plus cisplatin received
GC4419 by 60-minute intravenous infusion, ending <60 minutes before IMRT, Monday
through Friday for 3 to 7 weeks, in a dose and duration escalation study. Oral mucositis
was assessed twice weekly during and weekly after IMRT.
Results: A total of 46 patients received GC4419 in 11 separate dosing and
duration cohorts: dose escalation occurred in 5 cohorts receiving 15 to 112 mg/d over
3 weeks (nZ20), duration escalation in 3 cohorts receiving 112 mg/d over 4 to 6 weeks
(nZ12), and then 3 additional cohorts receiving 30 or 90 mg/d over 6 to 7 weeks (nZ14).
A maximum tolerated dose was not reached. One dose-limiting toxicity (grade 3 gastroenteritis and vomiting with hyponatremia) occurred in each of 2 separate cohorts at
112 mg. Nausea/vomiting and facial paresthesia during infusion seemed to be GC4419
doseerelated. Severe OM occurred through 60 Gy in 4 of 14 patients (29%) dosed for
6 to 7 weeks, with median duration of only 2.5 days.
Conclusions: The safety of GC4419 concurrently with chemoradiation for OCC was
acceptable. Toxicities included nausea/vomiting and paresthesia. Doses of 30 and
90 mg/d administered for 7 weeks were selected for further study. In an exploratory analysis, severe OM seemed less frequent and briefer than expected. Ó 2017 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
Oral mucositis (OM) is a common, disruptive, and painful
complication of radiation and chemoradiation (CRT) for
head and neck squamous cell carcinoma (HNSCC) (1).
Approximately 70% of patients receiving CRT for oral
cavity or oropharyngeal cancer (OCC) develop severe
OM, defined as grade 3 to 4 by the World Health Organization (WHO) scale (2, 3). Oral mucositis causes marked
pain requiring narcotic analgesics and adversely affects
nutrition, hydration, speech, swallowing, quality of life,
bacteremia risk, and feeding tube placement and use rates
(4, 5). Severe OM is also associated with radiation treatment breaks, which harms successful tumor management
(6-8). The financial cost of managing patients with severe
OM is substantial and is attributable to increased hospitalization and emergency room use (9, 10).
Recommended approaches to managing OM are limited
to palliation and pain control with topical agents and systemic analgesics (11-19). The only approved drug or biological to reduce OM, palifermin, is limited to patients at
risk for OM associated with conditioning regimens before
stem cell transplant for the treatment of hematologic malignancies (20, 21).
The pathogenesis of mucositis is a complex sequence of
biologic events in which oxidative stress plays a pivotal
initiating role (22). Therapeutic radiation causes radiolytic
hydrolysis and the formation of reactive oxygen species,
including superoxide anion (O2-). Superoxide is extremely
reactive, triggering a cascade of signaling pathways in the
cells and tissues of the submucosa and resulting in
apoptosis of epithelial stem cells, consequent loss of
epithelial renewal, atrophy, and mucosal ulceration (23).

A complement of naturally occurring superoxide
dismutase (SOD) enzymes exists to dispose of superoxide
(24). However, large, rapidly produced amounts of superoxide due to therapeutic radiation can overwhelm these
native SOD enzymes. GC4419 is a highly stable manganesecontaining macrocyclic complex (molecular weight Z 483),
whose activity mimics the native enzymes, selectively
removing superoxide anions without reacting with other
reactive oxygen species, including nitric oxide, hydrogen
peroxide, and peroxynitrite. An active enantiomer of
GC4419 protected mice from lethal total body irradiation
(25) and reduced radiation-induced OM in a hamster cheek
pouch model in a dose-related fashion (26). GC4419 had
equivalent effects in the same OM model but did not spare
tumor from the effects of CRT in multiple preclinical models
(Galera Therapeutics, unpublished data). Further, GC4419
protected mice from radiation-induced pulmonary fibrosis
(27).
The present study was done to assess the safety of
GC4419 in combination with radiation and concurrent
cisplatin for patients with OCC and to assess the potential
of GC4419 to reduce severe OM.

Patients and Methods
Patients
Eligible patients had oral cavity or oropharyngeal, stage IIIIVb HNSCC, Eastern Cooperative Oncology Group performance status 2, and a treatment plan that called for standard
fractionation intensity modulated radiation therapy (IMRT)
with concurrent cisplatin (80-100 mg/m2 every 3 weeks or
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30-40 mg/m2 weekly). The IMRT plan had to include at least
2 oral mucosal sites (right or left buccal mucosa, right or left
ventral/lateral oral tongue, floor of mouth, or soft palate)
within the cumulative 50-Gy isodose line. The IMRT plans
were centrally reviewed by an independent radiation
oncologist to confirm adherence to protocol requirements.
Adequate marrow, renal, and hepatic functions were
required. Prophylactic percutaneous endoscopic gastrostomy tube placement was allowed at enrollment. Patients
were excluded if they had prior induction chemotherapy,
significant dietary compromise due to reduced oral/pharyngeal function, or concurrent treatment with nitrates.
The protocol was approved by each institution’s institutional review board and was registered at ClinicalTrials
.gov. Investigators obtained written informed consent
from each participant. Data were anonymized to protect the
study subjects’ identities.

therapy; grade 4 anemia; grade 4 thrombocytopenia or
grade 3 associated with hemorrhage; grade 4 neutropenia
lasting >7 days; grade 3 or 4 febrile neutropenia; or other
grade 3þ events (except oral mucositis), judged by the
investigator not attributable to IMRT, cisplatin, or complications of HNSCC. For adverse events attributable to IMRT
or cisplatin but judged to be exacerbated by the presence of
GC4419, dose modification of GC4419 was at the investigator’s discretion. For any given patient, DLT required
the GC4419 dose to be reduced 1 dose level (ie, from
112 mg to 75 mg). Up to 2 such dose reductions per patient
were permitted. Six patients per cohort were enrolled if
DLT was observed in 1 of the first 3 patients. The maximum
tolerated dose (MTD) of GC4419 was defined as the
highest dose and longest schedule at which DLT was
observed in >1 patient in a single dose and schedule
cohort.

Treatment and study design

Study assessments and analysis

Intensity modulated radiation therapy was administered
once daily, Monday-Friday, at 2.0 to 2.2 Gy/d, to a cumulative tumor dose between 60 and 72 Gy. The
assigned dose of GC4419 was delivered intravenously in
normal saline over 60 minutes, ending within 60 minutes
before each radiation fraction. Oral rinses limited to
sodium bicarbonate, lidocaine, and antifungal agents
were permitted. Other concurrent available or experimental systemic or topical pharmaceuticals or devices,
or low-level laser therapy, were excluded. Supportive
care per American Society of Clinical Oncology guidelines, including antiemetic drugs for cisplatin, was
encouraged.
The study followed a serial cohort dose-escalation
design with 3 to 6 patients enrolled per cohort. The first
5 cohorts received GC4419 before each of the first 14
IMRT fractions (over approximately 3 weeks), reflecting
the duration of Investigational New Drug Applicationsupporting animal toxicology studies of GC4419. These 5
serial cohorts received 15, 30, 50, 75, or 112 mg of GC4419
per dose. These doses were based on previous results with a
single 15-minute infusion administered to healthy human
volunteers; the 60-minute infusion duration was chosen
because dogs tolerated higher doses administered more
slowly (ie, 12.5 mg/kg over 60 minutes vs 5 mg/kg over
15 minutes [Galera Therapeutics, unpublished observation]). On the basis of observed safety results in the first 5
cohorts, the protocol was then amended to allow “duration
extension” of GC4419 administered progressively longer
during IMRT. Three serial cohorts received 112 mg of
GC4419 before IMRT for 4, 5, or 6 weeks. Subsequent
review of safety and OM results through these cohorts led
to a decision by the sponsor to add 3 cohorts to extend
dosing further at reduced doses: 90 mg for 6 or 7 weeks or
30 mg for 7 weeks.
Dose-limiting toxicity (DLT) was defined as follows:
grade 3 or 4 nausea or vomiting despite maximal antiemetic

Adverse events were assessed using the National Cancer
Institute Common Terminology Criteria for Adverse
Events, version 4.0.
Oral mucositis was assessed by trained investigatorevaluators using WHO criteria, in which grade 0 Z no
mucositis; grade 1 Z pain and erythema; grade 2 Z
ulceration, able to eat solid food; grade 3 Z ulceration, able
to consume only liquids; grade 4 Z ulceration, inability to
eat requiring tube or parenteral feeding. Oral mucositis was
assessed twice weekly with at least a 48-hour interval between assessments during IMRT and weekly thereafter for
up to 8 weeks or until the WHO score was <2. Oral
mucositis assessment training and quality control were
performed by Clinical Assistance Programs (Framingham,
MA) to ensure that (1) all oral assessments were performed
in a consistent manner using standardized questions, oral
cavity examination technique and order, and data collection;
and (2) WHO grade scoring was correctly assigned per
assessment findings for all OM assessments. To reduce the
variability in assessing a patient’s diet, investigatorevaluators were trained to carefully elucidate whether dietary compromise was due to oral pain. If not, and the diet
was compromised by confounding factors (eg, dysgeusia,
edentulous, nausea, mucus, throat pain, functional
dysphagia), the WHO score was determined according to
what the patient said he or she could eat absent these confounding factors.
Plasma concentrations of GC4419 and major metabolites were measured, using a validated liquid chromatography/mass spectrometry method, before infusion, at the
end of infusion, and 1, 2, 4, and 6 to 8 hours after infusion
with 2 dosing cycles: week 1/day 2, and day 3 during the
last week of the infusion schedule.
Tumor status was assessed by clinical examination at the
end of IMRT and 3, 6, 9, and 12 months thereafter.
Standard-of-care imaging (computed tomography, positron
emission tomography, or magnetic resonance imaging) was
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done before and 3 and 12 months after IMRT. After
completion of the 12-month assessment, study follow-up
ended.
Statistical analysis of clinical endpoints was descriptive.
Severe OM incidence, time to onset, and duration were
tabulated. Patients who never developed OM grade >2 had
values of 0 days and >50 days imputed for duration and
onset, respectively, of severe OM. Phamacokinetics were
analyzed by noncompartmental analysis using the software
program Phoenix (WinNonlin Professional version 6.4;
PharSight, Mountain View, CA).

Results
Nine US centers enrolled 46 patients between August 2013
and June 2015. Patient characteristics are summarized in
Table 1. Forty-three patients completed OM assessments
and were considered evaluable for OM; 44 completed
tumor follow-up through 1 year after IMRT and were
evaluable for tumor endpoints (Table 2).

Safety
Initial cohorts received GC4419 for the first 14 days of
IMRT at 15 mg (nZ4), 30 mg (nZ3), 50 mg (nZ4), 75 mg
(nZ3), or 112 mg (nZ6). In these 5 cohorts, 1 toxicity
eventdgrade 3 nausea occurring at 112 mgdwas considered potentially drug-related and therefore dose limiting.

Table 1

Patient characteristics
Characteristic

Number

Total patients enrolled
Men/women
Age (y), median (range)
Primary tumor
Oral cavity
Oropharyngeal
Unknown
Postoperative/definitive treatment
Overall stage
III
IVA
IVB
Not available
Tumor HPV status
Positive
Negative
Not available
Cisplatin schedule
Every 3 wk
Weekly
Evaluable for OM assessment
Evaluable for tumor follow-up

46
38/8
58.5 (37-81)
7
38
1
18/28
2
39
4
1
25
2
19
39
7
43
44

Abbreviations: HPV Z human papillomavirus; OM Z oral mucositis.
Values are number unless otherwise noted.

Table 2

Distribution of patients by dose cohort

Dose cohort
15 mg/d  14
doses
30 mg/d  14
doses
50 mg/d  14
doses
75 mg/d  14
doses
112 mg/d  14
doses
112 mg/d  20
doses
112 mg/d  25
doses
112 mg/d  30
doses
90 mg/d  30
doses
90 mg/d  35
doses
30 mg/d  35
doses
Totals

No.
No.
No.
No. evaluable evaluable evaluable
enrolled for safety for OM for recurrence
4

4

4

4

3

3

3

3

4

4

4

4

3

3

3

3

8

8

6*

6*

3

3

3

3

3

3

3

3

5

5

3y

5

3

3

4z

3

6

6

6

6

4

4

4

4

46

46

43

44

Abbreviation as in Table 1.
* Two patients enrolled at 112 mg  14 doses withdrew early, and
two additional patients were enrolled in that cohort to complete safety
and efficacy analysis.
y
One patient was analyzed with the 90 mg/d  30 doses cohort and
1 patient limited OM evaluation to once weekly and thus was excluded
from OM analysis.
z
One patient enrolled at 112 mg/d  30 doses actually received
87 mg/d, per protocol provision, and is included with others at 90
mg/d  30 doses in OM analysis.

Ten of the 20 patients in these 5 cohorts completed treatment with no severe OM (Fig. 1). On the basis of the
favorable tolerability profile of GC4419 in these cohorts,
GC4419 dosing duration was extended by protocol
amendment, initially in 3 serial cohorts at 112 mgd20
doses/4 weeks, 25 doses/5 weeks, or 30 doses/6 weeks
(nZ3 each). In these 3 cohorts, one patient in the 112 mg/
6 weeks cohort had grade 3 nausea, which was considered
dose limiting. Because no single cohort had >1 patient with
DLT, the MTD was not considered exceeded. However, to
reduce the potential risk of nausea, the GC4419 dose was
lowered in the next 2 additional cohorts, to 90 mg for 30
doses/6 weeks (nZ4), and then 35 doses/7 weeks (nZ6).
Concurrently, another cohort received 30 mg for 35 doses/
7 weeks (nZ4).
Of 46 patients, 41 (89%) received all planned GC4419
infusions. Five patients, all at 112 mg, stopped GC4419
early for adverse events (nZ2) or patient request (nZ3),
receiving 2 of 14, 3 of 14, 9 of 14, 10 of 30, or 26 of 30
infusions. One additional patient (112 mg  30 doses) had
a permanent reduction to 75 mg for the last 6 doses
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Wk1

Wk2

Wk3

Wk4

Wk5

Wk6

Wk7

Radiation Therapy 2Gy/day Mon-Fri x 7 weeks

8

9

10

11
12
13
14
Post-Treatment Visits Weekly
Grade 3
Grade 4
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15

Partial Rx
3 week schedule
Multiple dose levels (n=20)

15mg
x
14 days
30mg
x
14 days
50mg
x
14 days
75mg
x
14 days
112mg
x
14 days

Full Rx
6-7 week schedules 30 or 90 mg/day
(n=14)

Intermediate Rx
4-6 week schedules
112 mg/day (n=9)

End of RT
112mg
x
20 days
112mg
x
25 days
112mg*
x
30 days
90mg
x
30 days

90mg
x
35 days

30mg
x
35 days

Fig. 1. Swimmers’ plot of oral mucositis scores for each evaluable patient (nZ43) over time, stratified by the 3 dosing
duration groups. Each horizontal bar (lane) provides World Health Organization scores for an individual patient during the
period of chemoradiotherapy (weeks 1-7) and after chemoradiotherapy (weeks 8-15, top of figure). Severe oral mucositis
grade 3 is denoted by yellow shading and grade 4 by red. Light blue within a lane denotes administration of GC4419. * One
patient enrolled at 112 mg  30 doses received 87 mg per protocol and is summarized with the 90 mg  30 dose cohort in
this figure.

because of grade 3 nausea; the other 40 received their full
doses.
The median total radiation therapy dose was 70 Gy
(<10 Gy for 2 early-withdrawing patients, 81.3 Gy for 1
patient, 66-70 Gy for all others). Radiation therapy breaks
of 5 or more consecutive fractions occurred in 3 of 46
patients (6.5%) (attributed to grade 3 nausea; respiratory
failure unrelated to GC4419; patient noncompliance). A
total of 9 patients (1 at 15 mg of GC4419, 2 at 30 mg, 3 at
90 mg, 3 at 112 mg), all receiving every-3-week platinum,
had their platinum doses reduced by 20% to 60% for the
second and/or third scheduled dose, at the discretion of the
treating investigator, because of adverse events attributed to
cisplatin. Four of the 9 patients received the full schedule of

GC4419 (1 30 mg/d  35 doses, 2 90 mg/d  35 doses, and
1 90 mg/d  30 doses), and another 3 of the 9 patients
received 112 mg/d (1  14 doses, 1  20 doses, and 1  30
doses).
Overall, adverse events, the most common of which
were cytopenias, nausea, fatigue, constipation, dysgeusia,
and dry mouth, were considered attributable to IMRT/
cisplatin, complications of HNSCC, or other concomitant
conditions. Although dose escalation of GC4419 was
curtailed before reaching a formal MTD, grade 3 nausea
or vomiting was more frequent at higher GC4419 doses
(Table 3), as was transient, infusion-related grade 1 facial
paresthesia that spontaneously resolved shortly after the
infusion and did not limit dosing.
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Table 3

Adverse events of note
15 mg
daily

Parameter

50 mg 75 mg
daily daily

30 mg daily

90 mg daily

112 mg daily

30 14, 20, 25,
25
20
14
35
30
14
14
35
14
14
or 30
total
total total total 14 or 35 total total total total 30 or 35 total total total
doses doses doses total doses doses doses doses doses total doses doses* doses doses doses* total doses

N
Paresthesia
(grade 1)
Nausea
(grade 3)
Vomiting
(grade 3)
Nausea
4
(any grade)

4
0

3
0

4
1 (25)

7
1 (14)

4
1 (25)

3
0

0

0

0

0

0

0

0

0

0

1 (25)

1 (14)

0

0

0

(100) 2 (67) 4 (100)

6 (86)

4
6
2 (50) 3 (50)

10
5 (50)

8
3
3
4
5 (63) 1 (33) 1 (33) 4 (100)

2 (33)

2 (20)

2 (25)

0

1 (33) 1 (25)

4 (22)

1 (16)

1 (10)

2 (25)

0

1 (33) 1 (25)

4 (22)

9 (90)

6 (75) 2 (67) 3 (100) 4 (100)

4 (100) 2 (67) 3 (75) 6 (100)

18
11 (61)

15 (83)

Values are number (percentage). Tabulated events are listed without regard to attribution to GC4419.
* A total of 5 patientsd3 in the 112 mg/14 dose cohort, and 2 in the 112 mg/30 dose cohortdreceived fewer infusions than planned, and 1 in the
112 mg/30 dose cohort had a permanent dose reduction to 75 mg. Also, one patient enrolled at 112 mg  30 doses received 87 mg per protocol and is
summarized with the 90 mg  30 dose cohort in this table. See text.

OM efficacy

in plasma (data not shown). The terminal elimination halflife was approximately 2 hours, with minimal accumulation
upon repeated dosing. There were 2 primary metabolites:
the major metabolite GC4520/parent GC4419 ratio was
approximately 10% at all dose levels, and the minor
metabolite GC4570/GC4419 ratio was <0.2% (data not
shown).

For patients who received 30 or 90 mg over the full 6 to
7 weeks of CRT, the cumulative incidence of severe OM
was 29% (4 of 14) through 6 weeks of RT (60 Gy), and
50% (7 of 14) at any time, with a median time to onset
>50 days, and a median duration of 2.5 days (Fig. 1,
Table 4). In contrast, in the initial 5 cohorts, GC4419 for
3 weeks was not as effective in reducing cumulative severe
OM through 60 Gy (incidence 40% and duration 4.5 days).
For patients in the intermediate treatment group, cumulative incidence at 60 Gy was 44%, at any time 67%, median
onset 43 days, and duration 18 days. Duration of all grades
of OM seemed to be shorter as GC4419 administration was
extended further in the IMRT treatment period (Fig. 2).

Tumor outcomes
Of 46 patients, 44 were evaluable for the 1-year tumor
outcome analysis (2 patients withdrew consent for followup; Table 5). Per study design, posteradiation therapy
follow-up was completed through 12 months for all 44 patients. Three patients died during the follow-up phase: 2
patients with oropharyngeal cancer died of noncancer causes
without evidence of progression, and 1 patient with
oropharyngeal cancer (human papillomavirus [HPV] negative) died from locoregional and distant recurrence at
6 months. Two additional patients with oropharyngeal cancer

Pharmacokinetics
Peak concentration and area under the concentration time
profile were approximately dose-proportional for GC4419
Table 4

Key OM efficacy parameters compared with historical controls
Comparative historical control

Severe OM (grades 3 and 4)
comparison of key efficacy
parameters
Incidence (%)
Through 60 Gy
At any time
Onset (d), median (range)
Duration (d), median (range)

GC4419 phase Ib/2a

Unpublished Placebo data from phase 3
data
trials
S. Sonis
(nZ380)
60
70
z28
26-30

Intermediate
Le et al (3) Henke et al (2) Partial treatment treatment (4-5þ wk) Full treatment
(nZ94)
(nZ94)
(nZ9)
(6-7 wk) (nZ14)
(3 wk) (nZ20)
57
69
35
26

62
67
32
22

40
50
>50 (25-57)
4.5 (0-77)

44
67
43 (15->50)
18 (0-68)

29
50
>50 (19->50)
2.5 (0-34)

Abbreviation as in Table 1.
Results for the 14 patients receiving 30 or 90 mg for 6-7 weeks are compared with those in the initial dose escalation phase (nZ20), the intermediate
schedule (nZ9), and representative historical controls. Patients who never developed OM of grade >2 had values of 0 days and >50 days imputed for
duration and onset, respectively, of severe (grade 3-4) OM.
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Grades 2-4

Partial Rx (n=20)
Pts Treated for 3 wks (14 days)

Grades 3-4
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Grade 4

Intermediate Rx (n=9)
Pts Treated for 4-5+ wks

Full Rx (n=14)
Pts Treated for 6-7 wks

120
100

Days

80
60
40
20
0

30 31 32 33 34 353637 38 39 40 41 42 43
21 222324 25 262728 29
1 2 3 4 5 6 7 8 9 10 11 12 13141516 171819 20

Patients

Fig. 2. Duration of all grades of oral mucositis decreased with longer GC4419 dosing. Each vertical set of bars represents
oral mucositis duration by grade for an individual subject. Data are presented by the 3 dosing duration groups (14 doses/
3 weeks; 4-5þ weeks; or 6-7 weeks) and arranged to increase from left to right for each subgroup for viewing clarity.
had locoregional progression at month 12 (1 HPV positive
and 1 HPV unknown), and 3 patients had distant metastases
at month 12. One of the 5 patients who experienced recurrence was in the full-dose cohort (90 mg  35 doses). None
of the 5 patients who experienced recurrence required
cisplatin dose reduction. Two of the 5 patients received 2 full
doses of cisplatin 100 mg/m2 but missed the last every-3weeks dose of cisplatin, 1 owing to patient noncompliance
and 1 owing to “administrative reasons.”

Discussion
In this study we found it feasible to add the SOD mimetic
GC4419 to IMRT and cisplatin. Observed safety was
acceptable at all dose and duration schedules studied. Delivery of planned CRT was not compromised in the presence of GC4419. Grade 3 nausea and vomiting were more
frequent at the highest dose (112 mg). Because of this, and
a low threshold for additional toxicity in this patient population, GC4419 dose escalation was curtailed before
reaching the study-defined MTD. The most common
GC4419-associated adverse eventdmild paresthesiadis
similar to reports with sublingual nitroglycerine (28) and is
Table 5 Summary of tumor outcome parameters for evaluable patients (nZ44)
Site

1-y LRC

1-y DM-free

Oral cavity 7/7 (100) 6/7 (86)
Oropharyn- 32/35 (91) 32/35 (91)
geal
Overall
39/42 (93) 38/42 (91)

1-y PFS

1-y OS

6/7 (86)
7/7 (100)
31/37 (84) 34/37 (92)
37/44 (84) 41/44 (93)

Abbreviations: DM Z distant metastases; LRC Z locoregional
control; OS Z overall survival; PFS Z progression-free survival.
Values are number (percentage). Locoregional control was defined as
alive without receiving alternate therapy and without locoregional
progression. Two patients who died of noncancer causes were censored
from the LRC and DM-free metrics, making the nZ42 for those
endpoints.

likely due to potentiation of nitric oxide (NO) by GC4419,
as has previously been reported to occur with this class of
compounds (29). Superoxide reacts rapidly with NO to
remove it, and abruptly reducing the amount of superoxide
present would be expected to potentiate NO’s effects.
The anticipated incidence, duration, and time to onset of
severe OM in this study were favorable compared with
historical controls (Table 4). These controls included the
placebo arms of 2 published studies of palifermin (2, 3) and
unpublished results known to one of the authors (Sonis)
from control arms of multiple prospective OM studies. The
unpublished historical controls are not case-matched with
the present study, and stage and HPV status are not available. The unpublished experience was limited to patients
with oral cavity or oropharyngeal primaries, postoperative
and definitive, who received IMRT plus concurrent
cisplatin (every 3 weeks or weekly). However, for all of
these published and unpublished historical data, mucositis
was assessed at sites receiving >50 Gy by the same OM
assessment criteria (trained assessors, assessment method,
assessment interval, WHO scale) as in the present trial.
Although conclusions from historical, cross-study comparisons must be limited, the present results are sufficiently
encouraging to warrant more rigorous assessment in a
prospective controlled trial.
Oral mucositis results were best for the cohorts that
received 30 or 90 mg of GC4419 for 6 to 7 weeks,
consistent with expectations that GC4419 should be
administered throughout the entire IMRT course to remove
superoxide produced with each IMRT fraction. Patients
receiving as little as 30 mg of GC4419 had little severe OM
(Fig. 1). Further, OM results through 6 weeks/60 Gy are of
interest because this is a common landmark expected to be
reached in IMRT of all patients with locally advanced
HNSCC.
Although most of our patients developed OM of WHO
grade 2, consistent with prior reports (4), severe (WHO
grade 3-4) OM is arguably more relevant to clinical benefit.
Reducing severe OM should decrease the substantial day-
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to-day burden of OM overall (5). As a result, increased
resource usage estimated to cost approximately $18,000 per
patient (10) could be reduced. A further question is whether
patients’ subjective reports of mouth and throat soreness
correspond to the WHO score, a relationship that held for
palifermin’s effects on OM in patients receiving total body
irradiation/high-dose chemotherapy and hematopoietic
stem cell transplant (30) but not in the trials of that drug in
HNSCC patients (2, 3).
Of equal importance, IMRT treatment breaks are
associated with compromised tumor outcomes in HNSCC
(7, 8). That only 3 of 46 patients (6.5%) in this study had
radiation therapy breaks of 5 or more consecutive fractions
is promising. Treatment breaks of this duration were reported in 15% of both control and experimental patients in
the 2 palifermin studies to reduce OM in HNSCC (2, 3),
which used 3-field conformal radiation, and 15.1% of patients receiving IMRT/platinum and 26.9% receiving
IMRT/cetuximab in the Radiation Therapy Oncology
Group 0522 trial (31).
For cancer supportive care agents, a major concern is
that they not compromise or antagonize the efficacy of the
underlying antitumor regimen. In the present study tumor
outcomes at 1 year did not seem unfavorable compared
with contemporary expectations (31), but conclusions are
limited owing to the small sample size and lack of a placebo arm for control.
On a mechanistic basis, GC4419 is expected not to
antagonize, but instead potentially enhance, tumor radiation
response. Normal and cancer cells metabolize reactive
oxygen species differently. Specifically, normal cells tend
to be more sensitive to elevations in superoxide anion but
more tolerant of increases in hydrogen peroxide flux. They
utilize redox protective enzyme systems to convert superoxide into water and molecular oxygen, removing it rapidly
to prevent normal tissue damage. Although these same
enzyme systems are typically active in cancer cells, moderate elevations in superoxide actually serve to promote
tumor growth, but significant increases in hydrogen
peroxide flux are apparently less well tolerated than for
normal cells (32). Thus, therapeutic radiation, by increasing
superoxide, can overwhelm the SOD enzyme system and
initiate normal tissue toxicity such as OM. GC4419 can
convert this excess superoxide into hydrogen peroxide,
which is less toxic to normal tissue, while simultaneously
maintaining or even increasing antitumor efficacy. Consistent with this are nonclinical data demonstrating synergy,
especially between GC4419 and higher dose-fraction RT
regimens (27), as are becoming used in stereotactic body
radiation therapy.
To our knowledge this is the first clinical trial of a selective SOD mimetic to reduce radiation therapyeinduced
severe OM. Results in animal models of radiation OM have
been reported for a manganese SOD (33), for nonselective
oxygen radical scavengers (34), and for manganese porphyrins that mimic both SOD and catalase (35). None of
these, however, has been tested in a clinical study of OM. A
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marketed bovine-sourced copper-zinc SOD was also tested
in a small study of head and neck cancer patients for
treatment of radiation toxicities in head and neck cancer
patients (36), but that product was subsequently withdrawn
from all markets for safety reasons.
The promising OM results of this study, along with a
comparative assessment of the contribution of GC4419 to
the toxicity and tumor control outcomes of CRT, must be
confirmed in a larger randomized, placebo-controlled
setting. To that end, doses of 30 and 90 mg/d administered throughout CRT were selected for the randomized,
double-blind, placebo-controlled GC4419 phase 2b trial in
progress. Tumor follow-up will extend through 24 months
after IMRT in that trial.
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